147 related articles for article (PubMed ID: 19801101)
1. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
Wachsberger P; Burd R; Ryan A; Daskalakis C; Dicker AP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):854-61. PubMed ID: 19801101
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models.
Chen J; Smith M; Kolinsky K; Adames V; Mehta N; Fritzky L; Rashed M; Wheeldon E; Linn M; Higgins B
Cancer Chemother Pharmacol; 2007 Apr; 59(5):651-9. PubMed ID: 16937104
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
4. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
5. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
Meyerhardt JA; Ancukiewicz M; Abrams TA; Schrag D; Enzinger PC; Chan JA; Kulke MH; Wolpin BM; Goldstein M; Blaszkowsky L; Zhu AX; Elliott M; Regan E; Jain RK; Duda DG
PLoS One; 2012; 7(6):e38231. PubMed ID: 22701615
[TBL] [Abstract][Full Text] [Related]
10. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
Brazelle WD; Shi W; Siemann DW
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):836-41. PubMed ID: 16751064
[TBL] [Abstract][Full Text] [Related]
11. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
[TBL] [Abstract][Full Text] [Related]
12. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
[TBL] [Abstract][Full Text] [Related]
14. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.
Williams KJ; Telfer BA; Shannon AM; Babur M; Stratford IJ; Wedge SR
Mol Cancer Ther; 2007 Feb; 6(2):599-606. PubMed ID: 17308057
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
[TBL] [Abstract][Full Text] [Related]
17. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Ren W; Korchin B; Lahat G; Wei C; Bolshakov S; Nguyen T; Merritt W; Dicker A; Lazar A; Sood A; Pollock RE; Lev D
Clin Cancer Res; 2008 Sep; 14(17):5466-75. PubMed ID: 18765538
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.
Tamura K; Takada M; Kawase I; Tada T; Kudoh S; Okishio K; Fukuoka M; Yamaoka N; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1997 Feb; 88(2):218-23. PubMed ID: 9119752
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]